NCT00573638Unknown不适用
The Effects of the Xal-Ease Delivery Aid Device on Patient Compliance With Xalatan Eye Drops
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 50
- 试验地点
- 2
- 主要终点
- The primary outcome measure is compliance with the medication XALATAN using and not using the Xal-Ease delivery aid for their glaucoma treatment.
研究概览
简要总结
The study hypothesis is that the Xal-Ease with increase patient compliance with XALATAN
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •40 to 80 years old
- •Diagnosis warranting treatment with Xalatan eye drops.
- •ambulatory and well functioning
排除标准
- •non-ambulatory
- •less than 40 or greater than 80 years old
- •Not using Xalatan eye drops
结局指标
主要结局
The primary outcome measure is compliance with the medication XALATAN using and not using the Xal-Ease delivery aid for their glaucoma treatment.
时间窗: six months
次要结局
- To determine if any of the other factors mentioned in the survey affect compliance to their medical regimen(six months)
- To see whether or not the Xal-Ease device helps patients conserve medication. ie - aids in drops not distilled in the eye.(6 months)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
4 期
Efficiency of XAL-EASE Device in Glaucoma and/or Ocular Hypertension (OHT) Patients, Treated With Xalatan or XalacomGlaucomaHypertensionNCT01125306Meir Medical Center50
已完成
4 期
Efficacy and Safety of Xiaflex Injection for Treatment of Dupuytren's Contracture of the ThumbDupuytren's ContractureNCT01265420Indiana Hand to Shoulder Center7
已完成
2 期
A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal CancerColorectal CancerNCT00048126Hoffmann-La Roche57
已完成
2 期
A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal CancerColorectal CancerNCT00048139Hoffmann-La Roche52
已完成
4 期
Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension.Glaucoma, Open-AngleOcular HypertensionNCT00140062Pfizer329